Profile picture

Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
Membership: HFA Member
Follow
Logo ESC

Contributor content

Adiposity-related anthropometrics, cardiovascular outcomes, and finerenone in heart failure and chronic kidney disease with type 2 diabetes: a FINE-HEART analysis
Presentation
Adiposity-related anthropometrics, cardiovascular outcomes, and finerenone in heart failure and chronic kidney disease with type 2 diabetes: a FINE-HEART analysis
Read more
Finerenone according to insulin resistance in heart failure: the FINEARTS-HF trial
Presentation
Finerenone according to insulin resistance in heart failure: the FINEARTS-HF trial
Read more
Opportunities to incorporate heart failure prevention strategies
Presentation
Opportunities to incorporate heart failure prevention strategies
Read more
Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials
Presentation
Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials
Read more
The HFpEF-ABA, H2FPEF, and HFA-PEFF scores and outcomes in individuals with HFpEF: a participant-level pooled analysis of 5 large-scale randomized clinical trials
Presentation
The HFpEF-ABA, H2FPEF, and HFA-PEFF scores and outcomes in individuals with HFpEF: a participant-level pooled analysis of 5 large-scale randomized clinical trials
Read more
Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Presentation
Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Read more
Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial
Presentation
Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial
Read more
Cardio-renal-metabolic overlap, outcomes, and treatment with dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
Presentation
Cardio-renal-metabolic overlap, outcomes, and treatment with dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
Read more

ESC 365 is supported by

novartis Explore sponsored resources